These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28749392)

  • 1. Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates.
    Shafiq N; Malhotra S; Gautam V; Kaur H; Kumar P; Dutta S; Ray P; Kshirsagar NA
    Indian J Med Res; 2017 Mar; 145(3):299-316. PubMed ID: 28749392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
    Burgess DS; Frei CR
    J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.
    Hsueh PR; Chen WH; Luh KT
    Int J Antimicrob Agents; 2005 Dec; 26(6):463-72. PubMed ID: 16280243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis.
    Wang J; Zhang H; Yan J; Zhang T
    J Matern Fetal Neonatal Med; 2022 Mar; 35(5):861-870. PubMed ID: 32102584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility profiles of gram-negative bacteria causing infections collected across India during 2014-2016: Study for monitoring antimicrobial resistance trend report.
    Veeraraghavan B; Jesudason MR; Prakasah JAJ; Anandan S; Sahni RD; Pragasam AK; Bakthavatchalam YD; Selvakumar RJ; Dhole TN; Rodrigues C; Roy I; Joshi S; Chaudhuri BN; Chitnis DS
    Indian J Med Microbiol; 2018; 36(1):32-36. PubMed ID: 29735823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper.
    Al Salman J; Al Dabal L; Bassetti M; Alfouzan WA; Al Maslamani M; Alraddadi B; Elhoufi A; Enani M; Khamis FA; Mokkadas E; Romany I; Somily A; Kanj S
    Int J Antimicrob Agents; 2020 Oct; 56(4):106104. PubMed ID: 32721603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population.
    Ang JY; Arrieta A; Bradley JS; Zhang Z; Yu B; Rizk ML; Johnson MG; Rhee EG
    Am J Perinatol; 2021 Jul; 38(8):804-809. PubMed ID: 31910460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS; Loeb M; Leto D; Brooks AA
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
    Fuchs A; Li G; van den Anker JN; Bielicki J
    Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Karlowsky JA; Lob SH; Siddiqui F; Akrich B; DeRyke CA; Young K; Motyl MR; Hawser SP; Sahm DF
    J Med Microbiol; 2023 Feb; 72(2):. PubMed ID: 36763081
    [No Abstract]   [Full Text] [Related]  

  • 16. Bacteriological profile and antibiotic susceptibility of neonatal sepsis in neonatal intensive care unit of a tertiary hospital in Nepal.
    Pokhrel B; Koirala T; Shah G; Joshi S; Baral P
    BMC Pediatr; 2018 Jun; 18(1):208. PubMed ID: 29950162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams.
    Gatti M; Pea F
    Expert Rev Anti Infect Ther; 2023 Feb; 21(2):149-166. PubMed ID: 36655779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli.
    Scudeller L; Righi E; Chiamenti M; Bragantini D; Menchinelli G; Cattaneo P; Giske CG; Lodise T; Sanguinetti M; Piddock LJV; Franceschi F; Ellis S; Carrara E; Savoldi A; Tacconelli E
    Int J Antimicrob Agents; 2021 May; 57(5):106344. PubMed ID: 33857539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.